AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 4:30 pm PT.
Interested parties can access the live and archived webcast of the presentation in the “News & Events”, “Events & Webcasts” section of the Globus Medical investor relations website at https://www.investors.globusmedical.com/news-events/events-webcasts.
About Globus Medical, Inc.
Based in Audubon, Pennsylvania, Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, regenerative biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.
Investor contact:
Brian Kearns
610-930-1800
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media contact:
Moran Chavez
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$71.01 |
| Daily Change: | -0.13 -0.18 |
| Daily Volume: | 554,774 |
| Market Cap: | US$8.080B |
March 06, 2025 February 20, 2025 February 06, 2025 January 08, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
